Zuranolone in the Room: Closing the Gap in Postpartum Depression Care

Picture a scene that probably feels familiar: A woman sits across from you, 6 weeks post partum, describing what she calls "not feeling like myself." Her Patient Health Questionnaire-9 score is 16. She is breastfeeding. She asks—quietly, as though she is not sure she is allowed to—whether there is something that could help her feel better quickly. And there is, as it happens. There has been, since 2023. But there is a real chance you have not prescribed it yet or have not had a chance to get comfortable with it. That is not a criticism—it is a gap worth closing.

Postpartum depression (PPD) affects approximately 1 in 8 women in the United States, making it the most common complication of childbirth.¹ It is underdiagnosed, undertreated, and—since 2023—uniquely addressable by a new class of medication. Zuranolone (Zurzuvae; Sage Therapeutics/Biogen) became the first oral treatment approved specifically for patients with PPD when the FDA cleared it in August 2023.² But real-world prescribing data from 2024 and 2025 tell a consistent story: Most eligible women are still not being offered this medication.³

Background: Why PPD Keeps Slipping Through

The DSM-5-TR defines PPD as a major depressive disorder (MDD) episode with peripartum onset—beginning during pregnancy or within 4 weeks of delivery—although the clinical window most of us work with extends to 12 months post partum, because that is when women actually show up.⁴ The consequences of untreated PPD reach further than the mother; documented downstream effects include impaired bonding, adverse infant neurodevelopmental outcomes, elevated maternal suicidality, and relationship rupture.⁵

Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) have been our workhorses here, and they do work. But in the postpartum context, they carry real limitations for both patients and clinicians. The 4- to 6-weeks wait for full therapeutic effect is not neutral when a woman has a newborn at home and is having difficulty feeling connected to her child. The lactation safety data for sertraline and paroxetine are reassuring,⁶ but that reassurance often gets lost somewhere between the prescription pad and the pharmacy—because patients are scared, clinicians are rushed, and nobody has 15 minutes to walk through the evidence on a busy intake day.

The 2023 US Preventive Services Task Force reaffirmation of universal perinatal depression screening is helping to identify more women with PPD.⁷ But identifying more patients only matters if we have a tool kit ready to meet them with. That is the argument for getting comfortable with zuranolone.

A Different Kind of Medication: The Neuroactive Steroid Pathway

The biology of neuroactive steroid treatment in PPD is one of the more elegant stories in recent pharmacology. During pregnancy, allopregnanolone—an endogenous positive modulator of γ-aminobutyric acid A (GABA-A) receptors—climbs to extraordinary levels. After delivery, it drops sharply. For women with a particular neurobiological vulnerability, this rapid hormonal withdrawal is hypothesized to drive the dysregulation that underlies PPD.⁸ This is not the same mechanism as a depressive episode triggered by life stress, which is part of why the response to a GABA-A–targeting drug can look so different, so much faster than what we typically see with serotonergic agents.

In March 2019, the FDA approved the first PPD-specific treatment, brexanolone (Zulresso; Sage Therapeutics), a synthetic intravenous (IV) formulation of allopregnanolone. Its phase 3 trial data were compelling, with meaningful symptom improvement within 48 to 72 hours.⁹ The problem was structural. A 60-hour IV infusion in a certified health care facility, under Risk Evaluation and Mitigation Strategy (REMS) requirements, with an infant at home—this was never going to reach most of the women who needed it. Brexanolone matters as a proof-of-concept and for the most severe inpatient cases. Zuranolone is what makes the mechanism practical.

Zuranolone is oral; a 5-mg dose is taken once daily for 14 days in the evening with a high-fat meal (to optimize bioavailability). No REMS. No facility certification. In the phase 3 ROBIN trial (NCT02978326), it demonstrated a statistically significant reduction in Hamilton Depression Rating Scale scores vs placebo, beginning at day 3 and maintained through day 45, 2 weeks after the final dose.¹⁰ If symptoms recur, the course can be repeated. That is the whole protocol.

A Case Worth Walking Through

“Mary,” a 33-year-old woman, presented at 8 weeks post partum. She was referred by her obstetrician, who had run an Edinburgh Postnatal Depression Scale (EPDS), on which Mary scored an 18. She had 1 prior depressive episode in her mid-20s, which was treated with therapy and resolved on its own. She was breastfeeding her daughter and had no interest in stopping, which she said flatly at the start of the appointment—the way people say things they expect to have to fight for.

She described persistent low mood, crying spells she could not explain, near-total anhedonia, and a specific kind of guilt that is almost pathognomonic of PPD—the guilt of not enjoying something you had wanted very much. She was not sleeping beyond what the baby's schedule allowed. She was not eating well. She had stopped calling friends.

Her psychiatrist discussed the options. SSRIs were on the table, as was zuranolone. The breastfeeding question was central: The prescribing label for zuranolone advises avoiding breastfeeding during the 14-day course and for 1 week after the final dose, based on pharmacokinetic data showing low but detectable transfer into breast milk.¹¹ Mary listened carefully. She had a freezer supply of pumped milk. Her mother was visiting. After a real conversation—not a 5-minute checklist—she decided to pause nursing for the duration of the course, use the stored milk and supplement with formula, and resume afterward.

By day 5, she sent a message through the patient portal: "I feel like a person again." Her EPDS score at the 2-week follow-up was 6. She resumed breastfeeding without difficulty. She did not require an SSRI. At 3 months, Mary remained in remission.

This case does not settle every clinical question about zuranolone. But it illustrates 2 things clearly: The speed of response is real and clinically significant, and breastfeeding—handled with time and honesty—is something most patients can work through.

Barriers and Comorbidities

The Table summarizes the most common barriers to prescribing zuranolone in outpatient settings, along with practical responses for each.¹²

Comorbid anxiety is present in approximately half of women with PPD.¹³ Data from a secondary analysis of phase 3 trial data demonstrate that zuranolone is associated with concurrent improvements in both depressive and anxiety symptoms—with higher rates of remission compared with placebo—but clinicians should monitor anxiety symptoms actively and consider adjunctive treatment when anxiety is the dominant presenting feature.¹⁴

Prior psychiatric history matters here more than in most contexts. Women with a personal or family history of MDD, bipolar disorder, or a previous PPD episode are at significantly elevated risk of recurrence. It is most effective to have the medication conversation before delivery, during the third trimester, when a plan can be made thoughtfully rather than reactively.

Regarding breastfeeding safety, results of a 2024 phase 1 pharmacokinetic study showed that zuranolone transfer into breast milk was low, with a relative infant dose well below the threshold generally considered compatible with breastfeeding.¹¹ Transfer is low but detectable. The guidance to pause during treatment and for 1 week after is precautionary and time-limited—not a life sentence or a moral judgment. Patients need to hear that.

5 Things to Take Into Your Next PPD Appointment

1. Zuranolone’s mechanism is different, and the speed reflects that. Zuranolone works through GABA-A modulation, not serotonin reuptake. That is why the response may take days rather than weeks. It is not a placebo effect, and it is not too good to be true.

2. Speed matters in the postpartum period. A 14-day course that begins working by day 3 is clinically meaningful in a way that few other psychiatric treatments are. For a woman in acute PPD distress, those weeks of latency on an SSRI are not neutral.

3. Breastfeeding is a conversation, not a contraindication. Most patients, given real information and real support, will make this decision. Your job is to make space for it, not to make it for them.

4. Screening creates obligation. If you are seeing more PPD because screening has improved, you have a responsibility to know what to do with what you are finding. Zuranolone should be in your tool kit.

5. Don't let cost assumptions close the door. Check prior authorization and patient assistance programs before assuming a patient cannot access this medication. The coverage landscape has improved significantly since approval.

Concluding Thoughts

Three years after the first oral PPD-specific medication was approved, there is still a large gap between what is available and what most women are being offered. That gap is no longer primarily a research problem. It is a clinical familiarity problem—one that practicing psychiatrists are uniquely positioned to address.

Zuranolone does not replace the therapeutic relationship. It does not resolve the exhaustion and isolation and grief that can accompany early parenthood. But it fills a specific, urgent clinical window for the woman in acute distress in the postpartum period, for whom speed of recovery is not just a preference but a matter of safety and her relationship with her child. The psychiatrist who can offer this treatment, navigate the breastfeeding discussion with honesty and patience, and follow the patient through recurrence risk is doing something that genuinely matters. That is worth being prepared for.

Dr Williams is a staff psychiatrist in the Women's Mental Health Program, with a clinical focus on perinatal mood and anxiety disorders, including postpartum depression.

References

1. Wisner KL, Sit DKY, McShea MC, et al. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry. 2013;70(5):490-498.

2. FDA approves first oral treatment for postpartum depression. FDA. News release. Updated August 22, 2023. Accessed June 3, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression

3. Meltzer-Brody S, Howard LM, Bergink V, et al. Postpartum psychiatric disorders. Nat Rev Dis Primers. 2018;4:18022.

4. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text revision. American Psychiatric Association; 2022.

5. Stein A, Pearson RM, Goodman SH, et al. Effects of perinatal mental disorders on the fetus and child. Lancet. 2014;384(9956):1800-1819.

6. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004;161(6):1066-1078.

7. US Preventive Services Task Force; Barry MJ, Nicholson WK, Silverstein M, et al. Screening for depression and suicide risk in adults: US Preventive Services Task Force recommendation statement. JAMA. 2023;329(23):2057-2067.

8. Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018;392(10152):1058-1070.

9. Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017;390(10093):480-489.

10. Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry. 2023;78(9):951-959.

11. Deligiannidis KM, Bullock A, Nandy I, et al. Zuranolone concentrations in the breast milk of healthy, lactating individuals: results from a phase 1 open-label study. J Clin Psychopharmacol. 2024;44(4):337-344.

12. O'Callaghan L, Chertavian E, Johnson SJ, Ferries E, Deligiannidis KM. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors in the treatment of postpartum depression. J Med Econ. 2024;27(1):492-505.

13. Wisner KL, Moses-Kolko EL, Sit DK. Postpartum depression: a disorder in search of a definition. Arch Womens Ment Health. 2010;13(1):37-40.

14. Deligiannidis KM, Citrome L, Huang MY, et al. Effect of zuranolone on concurrent anxiety and insomnia symptoms in women with postpartum depression. J Clin Psychiatry. 2023;84(1):22m14475.